Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease [PDF]
Endocrinology and Metabolism, 2023 Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular diseases; therefore, its prevention and treatment are important. The prevention of
Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
doaj +2 more sources
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground The mineralocorticoid receptor plays a significant role in the development of chronic kidney disease (CKD) and associated cardiovascular complications.
Ixchel Lima Posada +9 more
doaj +2 more sources
A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist [PDF]
Frontiers in Cardiovascular MedicineMultiple studies have shown that finerenone (BAY 94-8862), a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), possesses different or superior mechanisms of action to traditional MRAs.
Shuhui Zhai +3 more
doaj +2 more sources
Structural Mechanism of a Partial Glucocorticoid Receptor Agonist Functioning as a Mineralocorticoid Receptor Antagonist [PDF]
Structural DynamicsThe Glucocorticoid Receptor (GR) and Mineralocorticoid Receptor (MR) are homologous ligand-activated transcription factors that regulate extensive downstream gene expression networks involved in metabolism, development, electrolyte homeostasis, and ...
Xu Liu
doaj +2 more sources
Resolution of foveal detachment in dome-shaped macula after treatment by spironolactone: report of two cases and mini-review of the literature [PDF]
Clinical Ophthalmology, 2014 Ali Dirani,1 Alexandre Matet,1 Talal Beydoun,2 Irmela Mantel,1 Francine Behar-Cohen1–3 1Department of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Lausanne, Switzerland; 2Department of Ophthalmology, Hôtel-Dieu de Paris ...
Dirani A +4 more
doaj +3 more sources
Finerenone as a Nonsteroidal Mineralocorticoid Receptor Antagonist for Lupus Nephritis [PDF]
Kidney International ReportsMingfang Sun +4 more
doaj +2 more sources
Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors [PDF]
Kidney Research and Clinical Practice, 2022 Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis).
Anthony T. P. Chan, Sydney C. W. Tang
doaj +1 more source
Administration of finerenone in chronic kidney disease [PDF]
Journal of Nephropathology, 2023 Spironolactone is a first-generation and non-selective mineralocorticoid receptor antagonist (MRA). It is extensively well-studied and recommended due to increased accessibility for patients.
Mohsen Akhavan Sepahi +4 more
doaj +1 more source
American Journal of Ophthalmology Case Reports, 2023 Purpose: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use.
Mohamad El Wardani, Marc D. de Smet
doaj +1 more source
Thiazides and mineralocorticoid receptor antagonists in chronic kidney disease [PDF]
Romanian Journal of Medical Practice, 2022 The latest treatment guidelines for patients with arterial hypertension continues to indicate as the first line therapy a minimal association between renin-angiotensin system (RAS) blockers and a thiazide-type or a thiazide-like diuretic.
Andrei Niculae +5 more
doaj +1 more source